首页> 外文期刊>BMC Infectious Diseases >Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients
【24h】

Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients

机译:中国腹腔内感染患者大肠埃希菌和肺炎克雷伯菌分离株的发生率和抗菌药敏化趋势的更新

获取原文
           

摘要

To evaluate in vitro susceptibilities of aerobic and facultative Gram-negative bacterial (GNB) isolates from intra-abdominal infections (IAIs) to 12 selected antimicrobials in Chinese hospitals from 2012 to 2014. Hospital acquired (HA) and community acquired (CA) IAIs were collected from 21 centers in 16 Chinese cities. Extended spectrum beta-lactamase (ESBL) status and antimicrobial susceptibilities were determined at a central laboratory using CLSI broth microdilution and interpretive standards. From all isolated strains the Enterobacteriaceae (81.1%) Escherichia coli accounted for 45.4% and Klebsiella pneumoniae for 20.1%, followed by Enterobacter cloacae (5.2%), Proteus mirabilis (2.1%), Citrobacter freundii (1.8%), Enterobacter aerogenes (1.8%), Klebsiella oxytoca (1.4%), Morganella morganii (1.2%), Serratia marcescens (0.7%), Citrobacter koseri (0.3%), Proteus vulgaris (0.3%) and others (1.0%). Non- Enterobacteriaceae (18.9%) included Pseudomonas aeruginosa (9.8%), Acinetobacter baumannii (6.7%), Stenotrophomonas maltophilia (0.9%), Aeromonas hydrophila (0.4%) and others (1.1%). ESBL-screen positive Escherichia coli isolates (ESBL+) showed a decreasing trend from 67.5% in 2012 to 58.9% in 2014 of all Escherichia coli isolates and the percentage of ESBL+ Klebsiella pneumoniae isolates also decreased from 2012 through 2014 (40.4% to 26.6%), which was due to reduced percentages of ESBL+ isolates in HA IAIs for both bacteria. The overall susceptibilities of all 5160 IAI isolates were 87.53% to amikacin (AMK), 78.12% to piperacillin-tazobactam (TZP) 81.41% to imipenem (IMP) and 73.12% to ertapenem (ETP). The susceptibility of ESBL-screen positive Escherichia coli strains was 96.77%–98.8% to IPM, 91.26%–93.16% to ETP, 89.48%–92.75% to AMK and 84.86%–89.34% to TZP, while ESBL-screen positive Klebsiella pneumoniae strains were 70.56%–80.15% susceptible to ETP, 80.0%–87.5% to IPM, 83.82%–87.06% to AMK and 63.53%–68.38% to TZP within the three year study. Susceptibilities to all cephalosporins and fluoroquinolones were less than 50% beside 66.5% and 56.07% to cefoxitin (FOX) for ESBL+ Escherichia coli and Klebsiella pneumoniae strains respectively. The total ESBL+ rates decreased in Escherichia coli and Klebsiella pneumoniae IAI isolates due to fewer prevalence in HA infections. IPM, ETP and AMK were the most effective antimicrobials against ESBL+ Escherichia coli and Klebsiella pneumoniae IAI isolates in 2012–2014 and a change of fluoroquinolone regimens for Chinese IAIs is recommended.
机译:为了评估2012年至2014年间中国医院从腹腔内感染(IAIs)需氧和兼性革兰氏阴性细菌(GNB)分离株对12种选定的抗菌药物的体外敏感性。分别对医院收购(HA)和社区收购(CA)IAI从中国16个城市的21个中心收集。在中央实验室使用CLSI肉汤微稀释液和解释性标准品确定了超广谱β-内酰胺酶(ESBL)的状态和抗菌药敏性。在所有分离的菌株中,肠杆菌科细菌(81.1%)占45.4%,肺炎克雷伯菌占20.1%,其次是阴沟肠杆菌(5.2%),奇异变形杆菌(2.1%),弗氏柠檬酸杆菌(1.8%),产气肠杆菌(1.8) %),产酸克雷伯菌(1.4%),摩根氏摩根氏菌(1.2%),粘质沙雷氏菌(0.7%),科氏柠檬酸杆菌(0.3%),寻常变形杆菌(0.3%)和其他(1.0%)。非肠杆菌科细菌(18.9%)包括铜绿假单胞菌(9.8%),鲍曼不动杆菌(6.7%),嗜麦芽窄食单胞菌(0.9%),嗜水气单胞菌(0.4%)和其他(1.1%)。 ESBL筛查阳性大肠杆菌分离株(ESBL +)的趋势从所有大肠杆菌分离株的2012年的67.5%下降到2014年的58.9%,并且从2012年到2014年ESBL +肺炎克雷伯菌的分离株的百分比也下降了(40.4%降至26.6%) ,这是由于两种细菌在HA IAI中ESBL +分离株的百分比降低所致。所有5160个IAI分离株的总敏感性分别为对丁胺卡那霉素(AMK)的87.53%,对哌拉西林-他唑巴坦(TZP)的78.12%,对亚胺培南(IMP)的81.41%和对厄他培南(ETP)的73.12%。 ESBL筛查的阳性大肠杆菌菌株对IPM的敏感性为96.77%–98.8%,对ETP的敏感性为91.26%–93.16%,对AMK的敏感性为89.48%–92.75%对TZP,而ESBL筛查的阳性肺炎克雷伯菌肺炎的敏感性为在三年研究中,这些菌株易感ETP的70.56%–80.15%,对IPM敏感的80.0%–87.5%,对AMK敏感的菌株83.82%–87.06%和对TZP敏感菌63.53%–68.38%。 ESBL +大肠杆菌和肺炎克雷伯菌对所有头孢菌素和氟喹诺酮类药物的敏感性分别低于头孢西丁(FOX)的66.5%和56.07%。由于HA感染的发生率较低,大肠埃希菌和肺炎克雷伯菌IAI分离株的总ESBL +率降低。在2012-2014年间,IPM,ETP和AMK是最有效的抗ESBL +大肠埃希菌和肺炎克雷伯菌IAI分离物的抗菌剂,建议对中国IAI采取氟喹诺酮方案。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号